Q.+^ZN},Q{^EY/E4DW^>[A!VI|EBB
SYSTEM PROCESSING...
Q.+^ZN},Q{^EY/E4DW^>[A!VI|EBB
SYSTEM PROCESSING...
Posted: 2025-04-24 05:00:07 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-24 05:01:16 UTC
Verified By
Rollup News
The EMPATROPISM-FE trial, published in the European Heart Journal, investigates the impact of anaemia on iron homeostasis and the response to empagliflozin in heart failure patients with reduced ejection fraction.
Anaemia predicts myocardial iron content and systemic iron homeostasis dysregulation.
Empagliflozin's effects are modulated by anaemia status in heart failure patients.
Higher baseline T2* (lower MIC) correlated with lower haemoglobin and peak VO₂, adverse LV remodeling, and higher norepinephrine plasma levels.
Empagliflozin increased MIC and haematopoiesis, improved exercise capacity, depleted iron stores, and reduced norepinephrine levels.
Reverse LV remodeling was greater in patients with anaemia.
Reduced cellular iron uptake/availability may contribute to LV structural and functional impairment.
Close interrelations between myocardial T2* (MIC) and norepinephrine plasma levels suggest that sympatholytic effects of SGLT2 inhibitors may help explain their diverse cardiac and systemic benefits.